

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile



員工數Employee : 242

設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

資本額Capital：新台幣795佰萬元(NTD 795mn)

營業項目Business：

原料藥API (58.41%)

中間體Intermediate (30.61%)

特用化學品 Custom-made chemicals (10.98%)

公司概況 Outline

	Y2016	2017.Q2
歐洲 Europe	34.40%	45.06%
美洲 America	40.33%	18.03%
亞洲 Asia	11.77%	19.66%
國內 Taiwan	11.02%	16.04%
其他 others	2.48%	1.21%
合計 Total	100.00%	100.00%

製藥產業的上、中、下游 SCI's position

上游
Upstream

基本原料 RM



中間體 Intermediate:

生產原料藥之
中間步驟所產出之產品 Products before API



中游
Midstream

原料藥 API:

製劑中之有效成分 Curative ingredient



下游

Downstream

製劑: 成品藥 Formulation

旭富營業範圍
SCI's businesses

營運概況-IS

Unit: K NTD

	2017.Jan~May	2016Y
營收Sales	511,728	1,903,100
營業成本COGS	(359,928)	(1,112,574)
毛利Gross Profit	151,800	790,526
毛利率 GP Ratio	29.7%	41.5%
營業費用Operating Expenses	(56,844)	(274,069)
營業利益Operating Income	94,956	516,457
營業外損益Non-Operating In/Ex	(3,917)	(10,758)
稅前淨利 Net Profit before Tax	91,039	505,699
所得稅Income Tax		(88,744)
本期淨利Net Profit after Tax		416,955

產品組合-Products

Y2014	%		Y2015	%		Y2016	%
VA Series	21.89%		HOCLQ	21.52%		HOCLQ	34.94%
PGA	17.49%		VA Series	18.21%		PGA	12.73%
LPF.Na	8.74%		PGA	17.14%		VA Series	13.55%
S20/38	8.25%		LPF.Na	7.48%		Pent-2 / PEB.Na	6.70%
Pent-2 / PEB.Na	6.85%		5-HMT / 5-wing	4.61%		S-MMAA / Dulo	5.32%
5-HMT / 5-wing	4.65%		Pent-2 / PEB.Na	4.47%		5-HMT / 5-wing	5.21%
DBS	4.60%		S20/38	4.01%		LPF.Na	4.01%
S-MMAA / Dulo	2.64%		S-MMAA / Dulo	3.81%			
Total	75.11%		Total	81.25%		Total	82.46%

產品組合-Products


Product	%	2017 1H Sales (NT\$)
S-MMAA / Dulo	16.4	100,508,859
VA series	14.43	88,449,219
LPF.Na	11.96	73,264,404
Pent-2 / PEB.Na	9.36	57,362,144
5-HMT / 5-wing	9.23	56,582,452
PGA	5.43	33,264,396
MQRT-115	5.06	30,999,600

產品介紹Product

Hydroxychloroquine sulfate

✓ 風濕性關節炎藥物 For rheumatoid arthritis treatment

Unit : K NT\$




產品介紹Product

VA series-

Unit : K NT\$

Valproic Acid, Divalproex Sodium, Sodium Valproate



- ✓ 治療癲癇藥物
- ✓ Di-Va學名藥於2009推出


For epilepsy treatment

Di-Va generic came out in 2009

產品介紹Product

- Pyrogallolaldehyde (PGA) - Benserazide

Unit : K NT\$



✓治療帕金森氏症之中間體

Intermediate for Parkinson's Disease

產品介紹Product

Pent-2/Pentobarbital Sodium

Unit : K NT\$




- ✓ 鎮定安眠用中間體及原料藥
Intermediate and API for calmative

產品介紹Product

S-MMAA/Duloxetine

Unit : K NT\$



✓ 抗憂鬱症藥物 Antidepressant


✓ 2013年底Duloxetine專利到期

Duloxetine's patent expired in the end of 2013

產品介紹Product

5-HMT/Wing

Unit : K NT\$




- ✓ 愛滋病藥物中間體
For AIDS treatment
- ✓ Intermediates for Ritonavir and Lopinavir

產品介紹Product

Loxoprofen sodium

Unit : K NT\$



抗發炎藥物

Anti-inflammatory

日本市場200-300公噸

Japan market:200-300MT

GMP Status(GMP現況)

<i>API</i>	<i>CGMP Certified (TFDA)</i>	<i>CEP (EDQM)</i>	<i>DMF (USA)</i>	<i>MF (Japan)</i>	<i>DMF (Canada)</i>
Valproic Acid (*) (#)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011		
Sodium Valproate	2004	2006			
Divalproex Sodium (**)(#)	2005		2005		2010
Bisoprolol Fumarate	2006				
Pentobarbital Sodium	2009	2011			
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011	2014			
Duloxetine Hydrochloride	2012	2014	2010/2011		2016
Thiopental	2012				
Loxoprofen Sodium Hydrate	2012			2011	
Articaine Hydrochloride	2013	2014	2014		
Hydroxychloroquine Sulfate(#)	2014		2014		2014
Clindamycin Palmitate HCl			2011		
Cyclophosphamide	2014		2012		
Brinzolamide	2015		2015		
Probucol	2015		2004		2015
Atomoxetine HCl	2016				

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010, (#) FDA inspection: Dec. 2014.

簡報完畢



敬請指教